Weil Company’s Amicus Therapeutics FOLD Stock Holding History

Weil Company’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,840	Closed	-$250K	–	144
2020 Q4	$250K	Sell	10,840 -2,500	-19%	-$51.1K	0.15%	116
2020 Q3	$188K	Buy	13,340 +840	+7%	+$12.2K	0.14%	105
2020 Q2	$189K	Buy	12,500 +2,500	+25%	+$30.5K	0.16%	92
2020 Q1	$92K	Hold	10,000	–	–	0.09%	87
2019 Q4	$97K	Hold	10,000	–	–	0.07%	108
2019 Q3	$80K	Hold	10,000	–	–	0.06%	157
2019 Q2	$125K	Buy	+10,000	New	+$127K	0.1%	95

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Weil Company's FOLD Position: Q1 2021 in Review

Weil Company sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 10,840 shares — an estimated $250K sold.

Weil Company first reported a position in FOLD in Q2 2019 and held it in 7 quarters. The position peaked at $250K in Q4 2020. 258 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

Weil Company reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
Weil Company sold 10,840 Amicus Therapeutics shares in Q1 2021, an estimated $250K.
Weil Company first reported a position in Amicus Therapeutics in Q2 2019 and held it in 7 quarters.
Weil Company's Amicus Therapeutics position peaked at $250K in Q4 2020.
258 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Weil Company's 13F filing for Q1 2021, filed 12 May 2021.